We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

NantHealth, Oncotest-Teva Signs Reseller Deal

News   Dec 07, 2016

 
NantHealth, Oncotest-Teva Signs Reseller Deal
 
 
 

RELATED ARTICLES

Mining the Genome: Exploring Uncharted Territory To Discover New Drug Targets

News

Mining the rich uncharted territory of the genome, or genetic material of a cancer cell, has yielded "gold": new protein targets for drug development against prostate cancer. The team used state-of-the-art, whole-genome sequencing technologies on prostate tumor samples,to explore noncoding regions of the genome.

READ MORE

Advanced Bowel Cancers Lack “Molecular Flags” Keeping Them Hidden

News

Advanced bowel cancer cells have very few "molecular flags" on their surface, helping to explain why they may be hard for the immune system to detect, a new study has shown.

READ MORE

A Change in Cell Logistics Helps Cancer Become Resistant

News

Researchers have discovered that breast cancers which had become resistant to hormone therapy have a molecular "advantage" that helps the cells successfully evade hormone therapies.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Diagnostics Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE